Circulating microRNAs in nonalcoholic fatty liver disease

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 2, 2016, Pages 161-163

  DiStefano, Johanna K ^a   Gerhard, Glenn S ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; epigenetics; liver fibrosis; miRNA; NAFLD; NASH

Indexed keywords

MICRORNA; GENETIC MARKER;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FOLLOW UP; GENE EXPRESSION REGULATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; PATIENT MONITORING; REVIEW; BLOOD; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

DISEASE PROGRESSION; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84956770048     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1125290     Document Type: Review

References (27)

1. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease: current status and future directions. J Dig Dis. 2015;16(10):541-557
2. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015 Aug; 35 (3): 221-235
3. Gerhard GS, Benotti P, Wood GC, et al. Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity. Journal of Obesity. 2014; 2014: 1-8
4. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol: WJG. 2014; 20 (2): 475-485
5. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet. 2010; 375 (9724): 1419-1420
6. Kim DH, Saetrom P, Snove O Jr., et al. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A. 2008; 105 (42): 16230-16235
7. Gamazon ER, Innocenti F, Wei R, et al. A genome-wide integrative study of microRNAs in human liver. BMC Genomics. 2013; 14: 395
8. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013 Sep; 10 (9): 542-552
9. Enache LS, Enache EL, Ramiere C, et al. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci. 2014; 15 (10): 17644-17666
10. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3 (9): e3148
11. Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomic Proteomic Bioinform. 2015; 13 (1): 17-24
12. Javidi MA, Ahmadi AH, Bakhshinejad B, et al. Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids. Med Oncol. 2014 Dec; 31 (12): 295
13. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013 Feb; 57 (2): 840-847
14. Gerhard GS, DiStefano JK. Micro RNAs in the development of non-Alcoholic fatty liver disease. World J Hepatol. 2015; 7 (2): 226-234
15. Pirola CJ, Fernandez Gianotti T, Castano GO, et al. Circulating microRNA signature in non-Alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800-812
16. Miyaaki H, Ichikawa T, Kamo Y, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-Alcoholic fatty liver disease. Liver Int. 2014; 34 (7): e302-7
17. Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-Alcoholic fatty liver disease. Clin Chim Acta. 2015 Jun 15; 446: 267-271
18. Hasegawa Y, Kim SR, Hatae T, et al. Usefulness of Cytokeratin-18M65 in diagnosing non-Alcoholic steatohepatitis in Japanese population. Dig Dis. 2015; 33 (6): 715-720
19. Joka D, Wahl K, Moeller S, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012; 55 (2): 455-464
20. Thomas M, Deiters A. MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules. Curr Med Chem. 2013; 20 (29): 3629-3640
21. Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and non-Alcoholic fatty liver disease. PLoS One. 2011; 6 (8): e23937
22. Celikbilek M, Baskol M, Taheri S, et al. Circulating microRNAs in patients with non-Alcoholic fatty liver disease. World J Hepatol. 2014 Aug 27; 6 (8): 613-620
23. Zhang Y, Cheng X, Lu Z, et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res Clin Pract. 2013; 99 (3): 327-334
24. Petrick A, Benotti P, Wood GC, et al. Utility of ultrasound, transaminases, and visual inspection to assess nonalcoholic fatty liver disease in bariatric surgery patients. Obes Surg. 2015; 25 (12): 2368-2375
25. Tan Y, Ge G, Pan T, et al. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. Plos One. 2014; 9 (8): e105192
26. Leti F, Malenica I, Doshi M, et al. High-Throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res. 2015; 166 (3): 304-314
27. Abente EJ, Subramanian M, Ramachandran V, et al. MicroRNAs in obesity-Associated disorders. Arch Biochem Biophys. 2015. DOI: 10.1016/j.abb.2015.09.018. [Epub ahead of print]